register

News & Trends - Pharmaceuticals

BMS’ second-generation TKI now registered to treat children with Ph+ leukaemia

Health Industry Hub | July 6, 2020 |

Pharma News: Coping with a paediatric cancer diagnosis, including identifying the right treatment regimen, can take a significant physical and emotional toll on children and their families.

The Therapeutic Goods Administration (TGA) has expanded the indication for Bristol-Myers Squibb’s Sprycel (dasatinib) tablets to include the treatment of paediatric patients newly diagnosed with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukaemia (ALL) in combination with chemotherapy. 

Sprycel is the only second-generation tyrosine kinase inhibitor (TKI) approved for this patient population. 

The efficacy of Sprycel tablets in combination with chemotherapy was evaluated in a single cohort of the Phase 2, multicentre, single-arm CA180-372 study, which included paediatric patients with newly diagnosed B-cell precursor Ph+ ALL. At three years, the study demonstrated an event-free survival (EFS) binary rate of 64.1% (95% confidence interval [CI]: 52.4 to 74.7).

Acute lymphoblastic leukaemia is characterised by chromosomal abnormalities and genetic alterations involved in the differentiation and proliferation of lymphoid precursor cells. The most common childhood cancer, ALL represents 20% of all cancers diagnosed in persons aged less than 20 years, or more than 3,000 new cases each year. Only 3% of children who have ALL have the Ph+ subtype, which means they have a chromosome alteration that results in a specific mutation of the BCR-ABL gene.

In addition to this paediatric approval, Sprycel is approved for use in children with Ph+ chronic myeloid leukaemia (CML) in chronic phase (CP).


Human Resources

Medtronic HR Director deep dives into shifting workplaces and leadership trends: International HR Day

Medtronic HR Director deep dives into shifting workplaces and leadership trends: International HR Day

Health Industry Hub | May 20, 2024 |

People & Culture: Coinciding with International HR Day, Karen Newell, Senior HR Director for ANZ at Medtronic, joined Health Industry […]

More


News & Trends - MedTech & Diagnostics

Aussie medtech reveals new data on next-gen pulsed field ablation system for atrial fibrillation

Aussie medtech reveals new data on next-gen pulsed field ablation system for atrial fibrillation

Health Industry Hub | May 20, 2024 |

MedTech & Diagnostics News: An Australian-based medtech company announced promising results from the first-in-human study for its pulsed field ablation […]

More


News & Trends - MedTech & Diagnostics

Federal budget delivers 'mixed news' for radiologists

Federal budget delivers ‘mixed news’ for radiologists

Health Industry Hub | May 20, 2024 |

MedTech & Diagnostics News: The Royal College of Australian and New Zealand Radiologists (RANZCR) and the Interventional Radiology Society of […]

More


News & Trends - Pharmaceuticals

AstraZeneca, BMS and Noxopharm address findings of inquiry report into rare cancers

AstraZeneca, BMS and Noxopharm address findings of inquiry report into rare cancers

Health Industry Hub | May 20, 2024 |

Pharma News: The Senate Community Affairs References Committee has released its inquiry report into Equitable access to diagnosis and treatment […]

More


This content is copyright protected. Please subscribe to gain access.